This phase II trial is trying to determine how safe and tolerable a targeted therapy is for the treatment of several different cancer types.
This trial is treating multiple types of cancer including small-cell lung cancer, non-small cell lung cancer, squamous cell carcinoma of the head and neck, oesophageal cancer, stomach cancer and cancers of the gastro-oesophageal junction.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Seattle Genetics, Inc.
Patients with these tumours will be assigned to a study cohort as follows: Cohort 1: small cell lung cancer (SCLC) Cohort 2: non-small cell lung cancer-squamous (NSCLC-squamous) Cohort 3: non-small cell lung cancer-nonsquamous (NSCLC-nonsquamous) Cohort 4: head and neck squamous cell carcinoma (HNSCC) Cohort 5: esophageal squamous cell carcinoma (esophageal-squamous) Cohort 6: gastric and gastroesophageal junction (GEJ) adenocarcinoma. All patients, irrespective of the cohort, will receive ladiratuzumab vedotin as an intravenous monotherapy.
Recruiting Hospitals Read More